Cell News and Research

RSS

Majority of young adults support health reform legislation, says survey

An overwhelming majority-88 percent-of young adults across the political spectrum think it is important for Congress and the President to pass health reform legislation that would assure affordable health insurance for all and improve health care, according to a Commonwealth Fund survey released today.

19 Dec 2009

Annual diabetes Consumer Guide to be published in the January 2010 issue by Diabetes Forecast

When shopping for a new cell phone or even a car, there are dozens of features to explore and choices to make. The same is true of shopping for medical products that will help manage a chronic disease.

19 Dec 2009

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Neuralstem, Inc. today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA.

19 Dec 2009

Possible link between presence of breast cancer genes and infertility discovered

A New York Medical College physician who specializes in restoring or preserving fertility in female cancer patients has discovered a possible link between the presence of breast cancer genes and infertility.

19 Dec 2009

Understanding the differences between skull bone and bones in limbs could prevent osteoporosis

Scientists at Queen Mary, University of London have uncovered fundamental differences between the bone which makes up the skull and the bones in our limbs, which they believe could hold the key to tackling bone weakness and fractures.

19 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2009 and provided a business update.

18 Dec 2009

New stem cell based technology may eliminate brain cancer

Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing.

18 Dec 2009

UAB professors honored for scientific contributions and outstanding mentorship

Three University of Alabama at Birmingham (UAB) professors have been elected fellows of the American Association for the Advancement of Science (AAAS).

18 Dec 2009

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

18 Dec 2009

Researchers discover how protein can be controlled and under what circumstances it can go awry

A team of researchers studying the protein that, when defective or absent, causes cystic fibrosis (CF) has made an important discovery about how that protein is normally controlled and under what circumstances it might go awry.

18 Dec 2009

Human protein may help prevent H1N1 infection

Howard Hughes Medical Institute researchers have identified a naturally occurring human protein that helps prevent infection by H1N1 influenza and other viruses, including West Nile and dengue virus.

18 Dec 2009

Opexa Therapeutics completes registered direct offering

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series

18 Dec 2009

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

Australia's regenerative medicine company, Mesoblast Limited, today announced significant preclinical trial results showing that the proprietary adult stem cell platform could be an effective treatment for diabetes.

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

Cell News and Research

Majority of young adults support health reform legislation, says survey

Annual diabetes Consumer Guide to be published in the January 2010 issue by Diabetes Forecast

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Possible link between presence of breast cancer genes and infertility discovered

Understanding the differences between skull bone and bones in limbs could prevent osteoporosis

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

GSK receives European CHMP positive opinion for Revolade

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Rosetta Genomics announces third-quarter 2009 financial results

New stem cell based technology may eliminate brain cancer

UAB professors honored for scientific contributions and outstanding mentorship

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Researchers discover how protein can be controlled and under what circumstances it can go awry

Human protein may help prevent H1N1 infection

Opexa Therapeutics completes registered direct offering

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo